EX103, a Novel CD20xCD3 Bispecific Antibody, Showed a Favorable Safety and Potent Single-Agent Antitumor Activity in Heavily Pretreated Relapsed/Refractory Patients with BCell Non-Hodgkin Lymphoma

被引：1

作者：

Qi, Junyuan ^{[1
]}

Sun, Mingyuan ^{[1
]}

Zhou, Keshu ^{[2
]}

Ji, Chunyan ^{[3
]}

Lu, Fei ^{[3
]}

Chang, Chunkang ^{[4
]}

Zhang, Wenjun ^{[5
]}

Yang, Daniel ^{[5
]}

Lu, Jiali ^{[5
]}

Li, Jisen ^{[5
]}

Cheng, Ying ^{[5
]}

Li, Yanfei ^{[5
]}

机构：

[1] Chinese Acad Med Sci, GCP I Ward, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

[2] Zhengzhou Univ, Canc Hosp, Dept Hematol, Henan Canc Hosp, Zhengzhou, Peoples R China

[3] Shandong Univ, Dept Hematol, Qilu Hosp, Cheeloo Coll Med, Jinan, Peoples R China

[4] Shanghai Jiao Tong Univ, Sch Med, Dept Hematol, Shanghai Peoples Hosp 6, Shanghai, Peoples R China

[5] Guangzhou ExcelMab Inc, Dept Project Translat Med, Guangzhou, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173486

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 20 条

[1] EX103, a re-designed CD20xCD3 bispecific antibody, showed a favorable safety and potent single-agent antitumor activity in heavily pretreated relapsed/refractory patients with B cell non-Hodgkin lymphoma
Sun, M.
Zhou, K.
Ji, C.
Lu, F.
Chang, C.
Zhang, W.
Yang, D.
Lu, J.
Li, J.
Cheng, Y.
Li, Y.
Qi, J.
ANNALS OF ONCOLOGY, 2023, 34 : S547 - S548
[2] EX103: A newly designed CD20xCD3 molecule in heavily pre-treated patients with B-cell non-Hodgkin lymphoma from a phase I/II trial
Sun, Mingyuan
Qi, Junyuan
Zhou, Keshu
Liu, Xingchen
Hu, Kai
Chang, Chunkang
Wu, Dong
Li, Zhenling
Gong, Ming
Zhang, Wenjun
Yang, Daniel Chunxu
Lu, Jiali
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] MBS303, a Novel 2:1 CD20xCD3 Bispecific Antibody, Demonstrated a Favorable Safety and Potent Antitumor Activity in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma: Preliminary Results from a Phase I , Dose-Escalation Trial
Song, Yuqin
Yang, Haiyan
Jia, Youchao
Sheng, Lixia
Deng, Lijuan
Chen, Xi
Tang, Yongjing
Liu, Xifang
Liu, Sijun
Wei, Min
Li, Feng
BLOOD, 2024, 144 : 6481 - 6482
[4] Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20xCD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Brouwer-Visser, Jurriaan
Fiaschi, Nathalie
Deering, Raquel P.
Cygan, Kamil J.
Scott, Darius
Jeong, Se
Boucher, Lauren
Gupta, Namita T.
Gupta, Suraj
Adler, Christina
Topp, Max S.
Bannerji, Rajat
Duell, Johannes
Advani, Ranjana H.
Flink, Dina M.
Chaudhry, Aafia
Thurston, Gavin
Ambati, Srikanth R.
Jankovic, Vladimir
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (03)
[5] Infectious Complications in Patients with Relapsed or Refractory (R/R) Non-Hodgkin's Lymphoma (NHL) Treated with the Anti-CD20xCD3 Bispecific Antibody (BsAb) Mosunetuzumab
Shahid, Zainab
Okwali, Michelle
Joseph, Ashlee
Seo, Susan K.
Lue, Jennifer Kimberly
Boardman, Alexander P.
Caron, Philip
David, Kevin A.
Epstein-Peterson, Zachary D.
Ghione, Paola
Hamlin, Paul A.
Horwitz, Steven M.
Intlekofer, Andrew M.
Johnson, William
Kumar, Anita
Moskowitz, Alison
Noy, Ariela
Owens, Colette
Palomba, Maria Lia
Stuver, Robert
Torka, Pallawi
Vardhana, Santosha A.
Zelenetz, Andrew D.
Salles, Gilles
Falchi, Lorenzo
BLOOD, 2023, 142
[6] Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Xie, Yang
Cai, Qingqing
Liu, Haisheng
Guo, Ye
Huang, Wenrong
Zhang, Mingzhi
Xia, Yi
Gao, Yuhuan
Chen, Xilin
Tang, Yongjing
Yin, Shaoning
Yuan, Shunzong
Li, Haiying
Song, Yuqin
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[7] Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
Bannerji, Rajat
Arnason, Jon E.
Advani, Ranjana H.
Brown, Jennifer R.
Allan, John N.
Ansell, Stephen M.
Barnes, Jeffrey A.
O'Brien, Susan M.
Chavez, Julio C.
Duell, Johannes
Rosenwald, Andreas
Crombie, Jennifer L.
Ufkin, Melanie
Li, Jingjin
Zhu, Min
Ambati, Srikanth R.
Chaudhry, Aafia
Lowy, Israel
Topp, Max S.
LANCET HAEMATOLOGY, 2022, 9 (05): : E327 - E339
[8] Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma
Patel, Krish
Michot, Jean-Marie
Chanan-Khan, Asher
Ghesquieres, Herve
Bouabdallah, Kamal
Byrd, John C.
Cartron, Guillaume
Portell, Craig A.
Solh, Melhem
Tilly, Herve
Wierda, William G.
McGovern, Patricia
Johnson, Chelsea
Garcha, Raman
Ribrag, Vincent
Brisou, Gabriel
Liebowitz, David
Phillips, Tycel
BLOOD, 2021, 138
[9] Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Patel, Krish
Michot, Jean-Marie
Chanan-Khan, Asher A.
Salles, Gilles A.
Cartron, Guillaume
Peyrade, Frederic
Bouabdallah, Reda
Reid, Erin G.
Thomas, Sheeba K.
Wierda, William G.
Liebowitz, David
Pagel, John M.
Ribrag, Vincent
Saville, M. Wayne
Johnson, Chelsea M.
Ly, Thomas
Phillips, Tycel J.
BLOOD, 2019, 134
[10] A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Kim, Tae Min
Alonso, Arancha
Prince, Miles
Taszner, Michal
Cho, Seok-Goo
Stevens, Don A.
Poon, Michelle
Lim, Francesca
Le Gouill, Steven
Carpio, Cecilia
Keating, Mary-Margaret
Adriaens, Lieve
Ufkin, Melanie
Sabir, Ayesha
Li, Jingjin
Jankovic, Vladimir
Zhu, Min
Brouwer-Visser, Jurriaan
Leng, Siyang
Sirulnik, L. Andres
Chaudhry, Aafia
Ambati, Srikanth R.
Seog, Kim Won
BLOOD, 2020, 136

← 1 2 →